Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe active lupus, a retrospective study shows.
The Lupus Foundation of America describes lupus as a chronic disease that attacks the immune system, the part of the body ...
Pericarditis recurrence in lupus is more likely — and has a dose-dependent relationship — with oral prednisone treatment, ...
Lupus Alert Day serves a vital purpose. It encourages others to learn more about lupus, share information on social media, ...
Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.
After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...
Medicare covers lupus treatment in different ways depending on your age and how the condition affects you. Read more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback